Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative 5-fluorouracil + cisplatin + cetuximab in gastric and gastroesophageal junction adenocarcinoma
2010-023115-33Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Dec 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, cisplatin, fluorouracil and folinic acid in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoints: Composite primary endpoint, Objective response rate and 1 more. Started Dec 2010; status: completed.
02
Drugs
cetuximabcisplatinfluorouracilfolinic acid
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-023115-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023115-33.